

DCTN4 RABBIT PAB

货号: S217349

产品全名: DCTN4 兔多抗

基因符号: P62; DYN4

UNIPROT ID: Q9UJW0 (Gene Accession - BC026323)

背景: Dynactin is a multisubunit complex and a required cofactor for most, or all, of the cellular processes powered by the microtubule-based motor cytoplasmic dynein. Dynactin contains a short actin-related protein 1 (Arp1) filament with capZ at the barbed end and p62 at the pointed end. The p62 subunit is an integral component of 20 S dynactin with a highly conserved cysteine-rich motif that interacts directly with Arp1. Dynactin p62 has a punctate cytoplasmic distribution as well as centrosomal distribution typical of dynactin. In addition, Dynactin p62 is distributed in the nucleus at very high expression levels. Due to the structural composition of dynactin, the p62 subunit is implicated in Arp1 pointed-end binding and in linking dynein and dynactin to the cortical cytoskeleton.

抗原: Fusion protein of human DCTN4

经过测试的应用: ELISA, IHC

推荐稀释比: IHC: 50-200; ELISA: 2000-5000

种属反应性: Rabbit

克隆性: Rabbit Polyclonal

亚型: Immunogen-specific rabbit IgG


纯化: Antigen affinity purification

种属反应性: Human, Mouse, Rat


成分: PBS (without Mg²⁺ and Ca²⁺), pH 7.4, 150 mM NaCl, 0.05% Sodium Azide and 40% glycerol

研究领域: Signal Transduction


储存和运输: Store at -20°C. Avoid repeated freezing and thawing




Immunohistochemistry analysis of paraffin embedded Human cervical cancer tissue using 217349(DCTN4 Antibody) at a dilution of 1/30(Nucleus).



In comparison with the IHC on the left, the same paraffin-embedded Human cervical cancer tissue is first treated with the fusion protein and then with 217349(Anti-DCTN4 Antibody) at dilution 1/30.



The image on the left is immunohistochemistry of paraffin-embedded Human breast cancer tissue using 217349(Anti-DCTN4 Antibody) at a dilution of 1/30.



In comparison with the IHC on the left, the same paraffin-embedded Human breast cancer tissue is first treated with fusion protein and then with D22216(Anti-DCTN4 Antibody) at dilution 1/30.



Product Description

Pioneering GTPase and Oncogene Product Development since 2010
